摘要
目的评价聚乙二醇(PEG)干扰素联合利巴韦林治疗ALT正常的慢性丙型肝炎的临床疗效。方法使用聚乙二醇干扰素α-2a联合利巴韦林治疗20例ALT正常和25例ALT升高的慢性丙型肝炎患者。分别于治疗12周、48周及治疗结束后24周评价疗效,并观察药物副反应。结果ALT正常组所有患者均完成治疗,在治疗12周时的早期应答率为45%(9/20),治疗结束时的应答率为55%(11/20),在治疗结束后随访24周,持续应答率为45%(9/20)。2例患者在随访24周内出现ALT升高,血清HCVRNA阳转,复发率为18.2%(2/11),所有疗效指标与ALT升高组对比均无显著差异。结论PEG干扰素联合利巴韦林治疗ALT正常的慢性丙型肝炎同样具有较好的临床疗效,且副反应较轻。
Objective To evaluate the clinical effects of peginterferon and ribavirin treatment on chronic hepatitis C patients with normal serum alanine aminotransferase （ALT）. Methods 20 chronic hepatitis C patients with normal ALT and 25 patients with increased ALT were treated with peginterferon （ Pegasys） and ribavirin. Curative effect were evaluated at the 12,24 and 48 weeks during the treatment. The adverse effects of the treatment were evaluated at the same time. Result All patients with normal ALT completed the whole course of treatment. Following up studies were conducted at the 24th week after the treatment, The SVR was 45%（9/20）. At the 12th week during the treatment,the EVR was 45%（9/20）. At the end of treatment,the ETVR was 55% （11/20）. Two patients had an increase in ALT and HCV RNA level after the 24 weeks of treatment. The recurrence rate was 18.2%（2/11）. All the indexes had no statistically significant difference between the normal AL.T and increased ALT group. Conclusion Combination of peginterferon and ribavirin may be used for the treatment of ehronic hepatitis C patients with normal serum alanine aminotransferase. The side effect of treatment is slight.
出处
《实用肝脏病杂志》
CAS
2010年第1期39-41,共3页
Journal of Practical Hepatology
